Rifaquizinone
Rifaquizinone (RFQ, CBR-2092, TNP-2092) is an experimental antibiotic medication developed in China for the treatment of bacterial infections such as drug-resistant strains of ''Staphylococcus aureus''. It is an orally active prodrug which is also a codrug, being cleaved inside the body to two active components, with half of the molecule being a rifamycin derivative, and the other half a quinolone antibiotic. It is in clinical trials for joint infections following surgery and acute bacterial skin and skin structure infections. See also * Cefilavancin Cefilavancin (TD-1792) is an experimental antibiotic medication developed for the treatment of bacterial infections such as drug-resistant strains of ''Staphylococcus aureus''. It is a prodrug which is also a codrug, injected intravenously and th ... References {{reflist Antibiotics Heterocyclic compounds with 4 rings Quinolizidines Pyrrolidines Piperidines Acetate esters Carboxylic acids Carboxamides Methoxy compound ...
[...More Info...]       [...Related Items...]     OR:     [Wikipedia]   [Google]   [Baidu]